

Associazione
Culturale
ENEA



X International Workshop
on Lower Genital Tract Pathology
HPV Disease 2010 A.D.:
Coming into the Light
Viareggio 6-8 May 2010
Centro Congressi Principe di Piemonte

A grateful thank to:

Biolife Italiana Srl

Biomerieux Italia Spa

Diapath Spa

Explera a Qiagen Company

Gen-Probe Italia

GlaxoSmithKline Spa

Hologic Italia Spa

Innogenetics Srl

Libreria Studium Snc

Mtm Laboratories AG

Roche Spa

Sakura Italia Srl

Sanofi Pasteur Msd Spa

Provisional speakers and chairpersons

Atkins K.	Charlottesville, U.S.
Barbero R.	Asti, Italy
Biamonti A.	Rome, Italy
Boselli F.	Modena, Italy
Bondi A.	Bologna, Italy
Borruso F.	Verona, Italy
Carozzi F.	Florence, Italy
Cima G.P.	Camaioere, Italy
Costa S.	Bologna, Italy
Dalla Palma P.	Trento, Italy
Davies P.	Brussels, Belgium
Desai M.	Manchester, U.K.
Dexeus S.	Barcelona, Spain
Di Bonito L.	Trieste, Italy
Dillner J.	Malmö, Sweden
Dillner L.	Malmö, Sweden
Fambrini M.	Florence, Italy
Ferenczy A.	Montreal, Canada
Frega A.	Roma, Italia
French D.	Rome, Italy
Gentili C.	Carrara, Italy
Hirai Y.	Tokio, Japan
Huh W.	Birmingham, U.S.
Iossa A.	Florence, Italy
Iversen O.	Bergen, Norway
Marchionni M.	Florence, Italy
Marlow L.	London, U.K.
McGoogan E.	Edimburg, U.K.
Meijer C.	Amsterdam, The Netherlands
Miniello G.	Bari, Italy
Mojana G.	Milan, Italy
Moscicki B.	San Francisco, U.S.
Nappi O.	Naples, Italy
Navone R.	Turin, Italy
O'Leary J.	Dublin, Ireland
Penna C.	Florence, Italy
Perino A.	Palermo, Italy
Prandi S.	Reggio Emilia, Italy
Prendiville W.	Dublin, Ireland
Rossi R.	Florence, Italy
Scirpa P.	Rome, Italy
Stanley M.	Cambridge, U.K.
Szarewski A.	London, U.K.
Taddei G.L.	Florence, Italy
Tachezy R.	Prague, Czech Republic
Walker P.	London, U.K.
Waller J.	London, U.K.
Zanardi C.	Bologna, Italy

www.adriacongrex.it/hpv2010

Advanced Program

X International Workshop
on Lower Genital Tract Pathology
HPV Disease 2010 A.D.:
Coming into the Light

Scientific Secretariat

Cesare Gentili
Associazione Culturale ENEA
Viale Colombo, 57
54036 Marina di Carrara (MS)
Tel./ Fax + 39 0585 788284
E-mail: gentili.cc@libero.it

Co-organized by

Philip Davies
European Cervical
Cancer Association
68 cours Albert Thomas
69008 Lyon (France)
Tel./ Fax + 33 4 78 76 55 88
+ 33 4 78 76 55 97

Organizing Secretariat

ADRIA CONGREGX
Via Sassonia, 30
47900 Rimini (RN)
Tel.+39 0541 305811
Fax +39 0541 305842
E-mail: hpv2010@adriacongrex.it

Congress Venue

Centro Congressi
Principe di Piemonte - Viareggio (LU)
www.viareggiocongress.com

With the auspices of:



Associazione
Culturale
ENEA



Viareggio 6-8 May 2010
Centro Congressi Principe di Piemonte

Associazione
Culturale
ENEA



X International Workshop
on Lower Genital Tract Pathology
HPV Disease 2010 A.D.:
Coming into the Light
Viareggio 6-8 May 2010
Centro Congressi Principe di Piemonte

THURSDAY 6TH MAY

09.00 Registration

ROOM A - EDUCATIONAL WORKSHOP COLPOSCOPY AND THE MANAGEMENT OF CERVICAL DISEASE

Chairperson: **P. Scirpa**
09.30 Colposcopy in the HPV vaccine era - **P. Walker**
09.45 The basic principles and classifications - **S. Dexeus**
10.00 Functional changes of the transformation zone in the different ages of life - **C. Zanardi**
10.15 Atypical colposcopic features - **S. Dexeus**
10.30 Variation in standards of practice across Europe - **P. Walker**
10.45 The follow-up of HPV positive women: an evidence based algorithm - **C. Meijer**

SEMINAR OF COLPOSCOPY

Chairperson: **A. Frega**
11.00 My 3 hardest cases - **F. Boselli, G. Miniello, A. Biamonti**

ROOM B - HPV RESEARCH - SUMMARY OF THE LATEST ADVANCES

Chairperson: **S. Costa**
09.30 Natural history of HPV infection in women, our current understanding - **B. Moscicki**
09.45 Co-factors to HPV in cervical carcinogenesis - **J. Dillner**
10.00 HPV RNA detection: an overview of the evidence - **R. Tachezy**
RECENT ADVANCE IN CERVICAL CYTOLOGY AND CYTOPATHOLOGY

Chairperson: **S. Prandi**
10.15 Biomarkers to tell progressive from regressive cervical disease - **J. O'Leary**
10.30 LBC in cervical cytopathology - **E. McGoogan**
SEMINAR OF CYTOPATHOLOGY
Chairperson: **S. Prandi**
10.45 My 3 hardest cases - **L. Di Bonito, M. Desai, K. Atkins.**

ROOM A - MAIN CONFERENCE

12.20 Introduction: **C. Gentili**

I PLENARY SESSION - OPENING LECTURE

Chairperson: **C. Gentili**
12.30 Comprehensive programmes for cervical cancer prevention - **P. Davies**
EPIDEMIOLOGY OF HPV INFECTION
Chairperson: **O. Nappi**
12.50 Repeated infections in the young women: how often do they occur? - **B. Moscicki**
13.10 Is immigration changing the trend of HPV infection in Western Europe? - **J. O'Leary**
13.30 Questions and Answers
13.40 Lunch

II PLENARY SESSION - HPV & CERVICAL CANCER

Chairperson: **G.L. Taddei**
14.40 HPV: not just cervical cancer - **J. Dillner**
15.00 Men and cervical cancer - **B. Moscicki**
15.20 HPV infection; is there a role for measuring HPV antibody levels? - **J. Dillner**
15.40 Questions and Answers
15.50 Coffee Break

III PLENARY SESSION PREVENTION AND SCREENING

Chairperson: **P. Dalla Palma**
16.10 Update on HPV testing for primary screening. What are we waiting for? - **C. Meijer**
16.30 The implementation of HPV testing for cervical cancer screening; practical considerations - **A. Szarewski**
16.50 Organised cervical screening: is it worth the effort? - **P. Davies**
17.10 Introducing HPV vaccination into countries with established cervical screening programmes; practical considerations - **L. Dillner**
17.30 HPV vaccination: what effects do we expect to see and when do we expect to see them? - **A. Perino**
17.50 Questions and Answers
18.00 **ROUNDTABLE**
Chairperson: **R. Navone**
The Bethesda System and other cytological classifications: time for an update? **K. Atkins, M. Desai, Y. Hirai**

FRIDAY 7TH MAY

ROOM A - IV PLENARY SESSION HPV VACCINATION

Chairperson: **G. Mojana**
08.30 HPV vaccines: the mechanism of action - **M. Stanley**
08.50 HPV vaccination: "where we are now, where do we need to go?" - **J. Dillner**
09.10 HPV vaccination registries; do we really need them? - **L. Dillner**
09.30 HPV vaccination programmes: the current status in Europe - **P. Davies**
09.50 HPV vaccine cross protection; the data and the public health impact - **O. Iversen**
10.10 HPV vaccination: reducing the risk in sexually active adults? - **W. Huh**
10.30 Questions and Answers
10.40 Coffee Break

V PLENARY SESSION EDUCATION AND AWARENESS

Chairperson: **A. Iossa**
11.10 Difficult questions for clinicians about who and when to vaccinate - **P. Walker**
11.30 Awareness of HPV: what do people really know? - **J. Waller**
11.50 Sources of information about HPV and cervical cancer prevention - **L. Marlow**
12.10 Public health education and increasing the acceptance of HPV vaccination - **J. Waller**
12.30 The role of the physician in the prevention of cervical cancer - **L. Marlow**
12.50 Questions and Answers

ROOM B - FREE COMMUNICATIONS

Chairperson: **D. French**
8.30 Self collected HPV testing acceptability: comparison of two self sampling modalities **M. Sideri¹, S. Igidbashian¹, N. Spoltir¹, S. Boveri¹, D. Radice¹, M.T. Sandr¹**
¹Preventive Gynaecology Unit, IEO, Milan, Italy; ²Division of Epidemiology and Biostatistics, IEO, Milan, Italy; ³Laboratory Medicine Unit, IEO, Milan, Italy

8.40 L-Shape ENDO/ESOCervical Flocked Swab for improved Pap testing **E. Valagussa¹, P. Libretti¹, R. Colombo¹, M. Cadei¹, P. Grigolato¹, S. Castriciano¹**
¹Cytology Department, Fleming Labs, Brescia, Italy; ²Pathology Department, Ospedale Civile/Università di Brescia, Brescia, Italy; ³Copan Italia S.p.A., Brescia, Italy

8.50 HPV in semen of men participating in assisted reproduction protocols **O. Reich¹, P. Pürstner¹, R. Winter¹**
University of Graz, Graz, Austria

9.00 HPV prevalence and risk factors in a cohort of tuscan women aged 18-24 **C. Sani¹, F. Carozzi¹, M. Zappa¹, L. Ventura¹, A. Iossa¹, L. Brandigi¹, M. Franchini¹, F. Mirri¹, P. Viacava¹, A. Scarfantonio¹, D. Bazzanti¹, M. Confortini¹**
¹Analytical and Biomolecular Cytology Unit. ISPO, Florence, Italy; ²Clinical and Descriptive Epidemiology Unit. ISPO, Florence, Italy; ³Screening Unit. ISPO, Florence, Italy; ⁴Obstetrics and Gynecology Unit. Santa Maria Annunziata Hospital, Florence Italy; ⁵Departmental Section of Cytohistological for Oncological Screening. Montevarchi, Arezzo Italy; ⁶Pathological Anatomy Department, Ospedale Unico della Versilia, Viareggio, Lucca, Italy; ⁷Sanitary District of Valdarno, Montevarchi, Arezzo, Italy

9.10 Ubch10¹ expression in cervical intraepithelial neoplasia **C. Bellevedere¹, G. Troncione¹, D. Desiderio¹, M. Sansone², E. Acampora²**
¹Dipartimento di Scienze Biomorfologiche e Funzionali, University Federico II, Naples, Italy; ²Dipartimento di Ginecologia ed Ostetricia, University Federico II, Naples, Italy

9.20 Hybridization of nucleotide probes with HPV DNA: development of a new diagnostic tool **A. Lasso¹, G. Raugei¹, R. Cascella¹, C. Marconi¹, M. Zampagni¹, C. Cecchi¹, M. Fallani¹, G. Liguri¹**
¹University of Florence, Department of Biochemical Sciences, Florence, Italy; ²Hospitex Diagnostics srl, Sesto Fiorentino, Italy

9.30 Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer **M. Schrevel¹, S. Kolkman-Uljee¹, J.B.M.Z.Trimbos¹, G.J.Fleuren¹, A. Gorter¹, E.S. Jordanova¹**
¹Department of Pathology, Leiden University Medical Center (LUMC), Leiden, The Netherlands; ²Department of Gynaecology, Leiden University Medical Center (LUMC), Leiden, The Netherlands

9.40 Agreement between the abbot realtime high risk HPV test and the hybrid capture 2 in detection of HR HPV and diagnosis of high-grade cervical disease **F. Carozzi¹, E. Burroni¹, S. Bisanzi¹, G.Pontenani¹, C.Sani¹,M. Confortini¹**
¹ISPO, Analytical Cytology and Biomolecular Unit, Florence, Italy

9.50 Cervical cytology and HPV test in follow-up after conisation or lletz **D. Verša Ostojic¹, D. Vrdoljak-Mozetič¹, S. Štemberger-Papič¹, J. Gobič¹, S. Eminović²**
¹Department of Gynecological Cytology, University Department of Gynecology and Obstetrics, University Hospital Center Rijeka, Rijeka, Croatia; ²Department of Gynecology and Obstetrics, University Department of Gynecology and Obstetrics, University Hospital Center Rijeka, Rijeka, Croatia; ³Department of Pathology, School of Medicine, University of Rijeka, Rijeka, Croatia

10.00 What should we do if the result of histology indicates reconisation? HPV testing could replace histology? **R. Koiss¹, E. Babarcsi¹, C. Jeney¹, P. Gócze¹, P. Sikkós¹**
¹St. Stephan Hospital, Department of Obstetrics-Gynecology Budapest, Hungary; ²St. Stephan Hospital, Department of Pathology Budapest, Hungary; ³Genoid Molecular Diagnostic Laboratory, Budapest, Hungary; ⁴Scientific University of Pécs, Clinic of Obstetrics-Gynecology, Pécs, Hungary

10.10 P16^{INK4A} expression in endocervical, endometrial and metastatic uterine adenocarcinomas **M.A. Caponio¹, T. Addati¹, M. Deliso², G. Falco², G. Giannone¹, S. Petroni¹, V. Rubini¹, G. Simone¹**
¹UO Anatomia Patologica, Istopatologia e Biotecnologia Avanzate, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy; ²UO Ginecologia, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy

10.20 Immunogenic efficacy of quadrivalent vaccine-induced antibody titres against HPV 6/11/16/18 in women aged 26-45 years: preliminary findings **A. Biamonti¹, A. Pacchiarotti², B. Virgilio¹, T. Bernardini¹, D. French¹**
¹"Cristo Re" Hospital, Rome, Italy; ²Il Faculty of Medicine, "Sapienza" University, Rome, Italy

10.30 Efficacy of lactoferrin-beta-glucan in management of ascus/lsil: preliminary results **M. Sansone¹, A. Capone¹, E. Acampora¹, S.M. Celotto¹, A. Vallefucio¹, M.S. Lanni¹, P.Martinelli¹**
Dipartimento Clinico di Ginecologia Ostetrica e Fisiopatologia della riproduzione umana., Area funzionale: Emergenze ostetriche e ginecologiche, Università degli studi Napoli Federico II, Naples, Italy

10.40 Coffee Break
11.10 **NEW TECHNOLOGIES IN CERVICAL CANCER SCREENING**

Chairperson: **F. Carozzi**
12.10 **THE VACCINE: WHAT ARE THE OPTIONS?**
Chairperson: **F. Borruso**
13.10 Lunch

ROOM A - I CLINICAL SESSION NEW ISSUES IN COLPOSCOPY PRACTICE

Chairperson: **M. Marchionni**
14.30 The European Colposcopy Guidelines - **P. Walker**
14.50 CIN: two-disease concept "for the last time" - **A. Ferency**
15.10 See and treat; results from clinical practice in Europe - **W. Prendiville**
15.30 Colposcopy: how to get the best out of it - **A. Ferency**
15.50 Questions and Answers
16.00 Coffee Break

II CLINICAL SESSION TREATMENT AND FOLLOW-UP

Chairperson: **R. Rossi**
16.30 Adverse obstetrical outcomes after treatment of CIN; a summary of the data - **W. Prendiville**
16.50 Adverse obstetrical outcomes; are treatment and follow-up practices changing? - **S. Dexeus**
17.10 Management of recurrent CIN - **R. Barbero**
17.30 Questions and Answers

III CLINICAL SESSION HPV DISEASES OF THE VULVA, VAGINA AND PENIS

Chairperson: **M. Fambrini**
17.40 Treatment of genital warts; what is new and what is not - **C. Penna**
18.00 Genital warts: a review of HPV vaccine efficacy - **M. Stanley**
18.20 EGW's: traditional and off-label therapies - **A. Ferency**
18.40 Questions and Answers
18.50 Adjourn

ROOM B - I CYTOPATHOLOGY SESSION OLD PROBLEMS, NEW SOLUTIONS

Chairperson: **P. Dalla Palma**
14.30 Screening and Cervical cytology: new trends in Japan - **Y. Hirai**
14.50 LBC; not only morphology - **E. McGoogan**
15.10 Computer assisted screening; comparing the options - **M. Desai**
15.30 Cervical cytology specimen adequacy: does LBC make a difference - **Y. Hirai**
15.50 Questions and Answers
16.00 Coffee Break

II CYTOPATHOLOGY SESSION MOLECULAR BIOLOGY IN THE CYTOLOGY LABORATORY

Chairperson: **A. Bondi**
16.30 Methylation markers: what they are and how they can be used in HPV screening - **C. Meijer**
16.50 Molecular markers to improve the accuracy of pap smears - **J. O'Leary**
17.10 HPV testing for quality control of cytology: a new opportunity - **F. Carozzi**
17.30 Questions and Answers

III CYTOPATHOLOGY SESSION UNANSWERED QUESTIONS IN DIAGNOSIS

Chairperson: **S. Prandi**
17.40 ASCH or HSIL; what are the differences - **K. Atkins**
18.00 The AGC Pap: management and follow-up - **A. Ferency**
18.20 Morphologic signs of viral integration - **K. Atkins**
18.40 Questions and Answers
18.50 Adjourn

SATURDAY 8TH MAY

ROOM A - IV PLENARY SESSION SOME UNANSWERED QUESTIONS

Chairperson: **C. Gentili**
08.30 Guidelines for Pap testing, HPV testing and colposcopy in adolescents - **B. Moscicki**
08.50 HPV persistence but no disease: what should we do next? - **O. Iversen**
09.10 Second generation prophylactic HPV vaccines; what is on the horizon? - **A. Szarewski**
09.30 Whatever happened to the therapeutic HPV vaccines? - **M. Stanley**
09.50 Questions and Answers

ROOM A - IV CLINICAL SESSION PRACTICAL ISSUES IN THE MANAGEMENT OF CERVICAL DISEASE

Chairperson: **G.P. Cima**
10.10 The management of cervical intraepithelial neoplasia during pregnancy: is colposcopy necessary? - **W. Huh**
10.30 Defining thresholds for investigation and treatment for women age 20-25+ - **P. Walker**
10.50 After treatment for CIN, what is the residual risk - **W. Prendiville**
11.00 ASC-US and high-risk HPV testing: performance in daily clinical practice - **W. Huh**
11.20 Conclusions

ROOM B - IV CYTOPATHOLOGY SESSION PRACTICAL ISSUES IN THE DIAGNOSIS

Chairperson: **R. Navone**
10.10 Atrophic vaginitis versus invasive squamous cell carcinoma on ThinPrep cytology: can the background be reliably distinguished? - **E. McGoogan**
10.30 Atypical glandular cells, distinguishing artefact from true lesions in LBC specimens - **H.Hirai**
10.50 Cytological features of squamous cells involving endocervical glands - **L. Di Bonito**
11.00 Histologic implications of Pap smears classified as atypical glandular cells - **K. Atkins**
11.20 Conclusions